Discontinued — last reported Q4 '21
Biogen Income taxes payable – long-term increased by 4.7% to $174.20M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 7.5%, from $162.10M to $174.20M. Over 5 years (FY 2020 to FY 2025), Income taxes payable – long-term shows a downward trend with a -25.2% CAGR.
An increase may indicate deferred tax liabilities growing due to timing differences, while a decrease suggests the settlement of long-term tax obligations.
This represents the portion of income tax liabilities that are expected to be settled beyond the next twelve months. It...
Commonly found in most capital-intensive firms with complex global tax structures.
other_accrued_income_taxes_noncurrent| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $652.70M | $657.60M | $664.50M | $640.50M | $499.60M | $559.70M | $541.70M | $552.50M | $383.30M | $393.80M | $403.20M | $411.00M | $191.70M | $162.00M | $156.70M | $162.10M | $165.10M | $164.70M | $166.40M | $174.20M |
| QoQ Change | — | +0.8% | +1.0% | -3.6% | -22.0% | +12.0% | -3.2% | +2.0% | -30.6% | +2.7% | +2.4% | +1.9% | -53.4% | -15.5% | -3.3% | +3.4% | +1.9% | -0.2% | +1.0% | +4.7% |
| YoY Change | — | — | — | — | -23.5% | -14.9% | -18.5% | -13.7% | -23.3% | -29.6% | -25.6% | -25.6% | -50.0% | -58.9% | -61.1% | -60.6% | -13.9% | +1.7% | +6.2% | +7.5% |